NCT03729219View on ClinicalTrials.gov

Prevention of Diarrheal Disease Due to Infection With Enterotoxigenic E. Coli (ETEC)

PHASE2CompletedINTERVENTIONAL
Enrollment

749

Participants

Timeline

Start Date

June 12, 2017

Primary Completion Date

April 15, 2019

Study Completion Date

April 15, 2019

Conditions
Diarrhea
Interventions
BIOLOGICAL

E. coli ETVAX

Oral suspension Sterile water is added to dmLT . Vaccine is poured to the effervescent solution and needed amount of dmLT is added.

OTHER

Placebo

Oral suspension

Trial Locations (1)

Unknown

Lääkärikeskus Aava, matkailuklinikka, Helsinki

All Listed Sponsors
collaborator

Göteborg University

OTHER

collaborator

United Medix Laboratories Ltd.

UNKNOWN

collaborator

Oy Medfiles Ltd

INDUSTRY

collaborator

University of Helsinki

OTHER

collaborator

University of Virginia

OTHER

lead

Scandinavian Biopharma AB

INDUSTRY

NCT03729219 - Prevention of Diarrheal Disease Due to Infection With Enterotoxigenic E. Coli (ETEC) | Biotech Hunter | Biotech Hunter